Gaurav's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • Q2 2024
Question
Gaurav asked for the vision to integrate Exscientia's generative AI capabilities into the new company, following Recursion's previous acquisitions of Cyclica and Valence.
Answer
Najat Khan, Chief R&D and Commercial Officer, detailed the integration strategy, focusing on leveraging Exscientia's end-to-end active learning for multi-parameter optimization in molecular design. She stated this would improve the probability of success from hit-to-lead and lead optimization. Khan emphasized that the platforms' modular design would facilitate a smooth integration, allowing the combined company to use the best models available.